Key Highlights

  • Australian stimulated-cycle market contracted 3.2% in Q1 FY27 relative to Q4 FY26
  • MVF expects FY27 underlying NPAT to be materially below FY26 and current analyst consensus estimates
  • Structural productivity transformation program targeting $8-11 million annualised savings, though benefits now expected over a longer period
  • 12-month rolling Market Share of 19.4% was broadly in line with the 30 June 2026 position

Monash IVF Group Limited (ASX:MVF) has provided a trading update for the period from 1 July 2026 to 20 November 2026, flagging that the company expects its underlying FY27 NPAT to be materially below FY26 and current analyst consensus estimates. The outlook reflects a combination of a contracting IVF market, above-inflation cost increases, delayed benefits from cost initiatives, and the ramp-up of new capacity.

Market Conditions and Share Position

The Australian stimulated-cycle market contracted by 3.2% in Q1 FY27 relative to Q4 FY26, with ongoing month-to-month volatility. MVF's 12-month rolling market share of 19.4% was broadly in line with market share at 30 June 2026 against industry stimulated cycles that decreased 0.5%. Market share improved in all states during Q1 FY27 compared to Q4 FY26 except in South Australia, where new local competitive pressures resulted in share loss.

Trading momentum in October and November delivered improved Earnings performance against Q1 FY27, as a result of combined Volume growth and execution of the structural productivity program. The company's international operations continue to perform from a small base.

Cost Pressures and Transformation Program

MVF is responding to Fixed Cost base increases that have risen above domestic Inflation rates, particularly in occupancy costs of new facilities ahead of activity, wages, insurance premiums, and above-inflation price increases from some key suppliers. The company's structural productivity transformation program remains ongoing and is targeted to deliver $8-11 million in annualised pre-tax savings, although earnings benefits are now expected to be realised over a longer period than previously anticipated.

Key actions underway include organisational right-sizing through FTE reduction, procurement negotiations, and discretionary spending controls. Depreciation and interest expenses are also expected to be higher than FY26 as a result of Investment in increased capacity and higher Debt levels.

Capacity Investment and Facility Updates

MVF's major infrastructure investment is now largely complete, with the focus shifting from building capacity to utilisation. The company's Brisbane operations experienced a temporary closure during July 2026 while transitioning to a new facility, with the new Brisbane location ramping activity to reach a steady state by end of Q2. The new Clayton facility is on track to open in December 2026, while the Cremorne facility has more than doubled theatre utilisation with a 22% increase in volumes between Q4 and Q1.

The board does not consider there is a sufficiently reliable basis to provide quantitative earnings guidance for FY27 at this time and intends to provide a further trading update with the half-year results.